Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer

Inclusion Criteria

• •Patients who are 18 years or older;
• •Patients with histological or, if not possible, cytologic confirmed adenocarcinoma of the pancreas.
• •Patients with metastatic pancreatic cancer;
• •Patient with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2
• •Adequate hematopoietic, hepatic and renal function:
• •Neutrophil count \>= 1.5 x 10\*9/L;
• •Platelet count \>= 100 x 10\*9/L;
• •Bilirubin \<= 1.5 x ULN;
• •AST and/or ALT \<= 2.5 x ULN;
• •Serum creatinine \<= 1.5 x ULN.
• •Investigators must ensure that patients enrolled in the study will be available for all study procedures, including tumor biopsy, chemotherapy treatment, and follow up.
• •Investigators must ensure that patients have the ability to understand the requirements of the study and provide signed informed consent.
• •Women of childbearing potential and men who wish to participate in the study must agree to use adequate contraception since the signing of informed consent until at least 3 months after stopping the study medication;
• •Signed Informed Consent.